Poor
Not Aligned
Patient Risk:
Medium
Summary
None of the extracted claims can be verified against the supplied FDA-approved prescribing information because no label sections/text or citations were provided; the evaluator marked every claim as absent from the label and several safety-related statements use specific wording (e.g., “rebound effect”) that cannot be confirmed.
Category Scores
Accurate Statements
Unsupported Statements
Cosentyx (secukinumab) is a biologic medication used to treat moderate to severe plaque psoriasis.
Evaluator decision: absent from the label; no label citation/text provided to verify.
Cosentyx (secukinumab) is a biologic medication used to treat psoriatic arthritis.
Evaluator decision: absent from the label; no label citation/text provided to verify.
Cosentyx (secukinumab) is a biologic medication used to treat ankylosing spondylitis.
Evaluator decision: absent from the label; no label citation/text provided to verify.
Cosentyx works by blocking the action of interleukin-17A (IL-17A).
Evaluator decision: absent from the label; no label citation/text provided to verify.
Cosentyx is administered via injection.
Evaluator decision: absent from the label; no label citation/text provided to verify.
Adhering to the prescribed dosage of Cosentyx is crucial for maintaining its effectiveness.
Evaluator decision: absent from the label; no label citation/text provided to verify.
Stopping or reducing Cosentyx without consulting a doctor can lead to a rebound effect where disease symptoms worsen.
Evaluator decision: absent from the label; no label citation/text provided to verify specific wording/claim.
Reducing or stopping Cosentyx can lead to a rebound effect where disease symptoms worsen.
Evaluator decision: absent from the label; no label citation/text provided to verify.
For psoriasis patients, disease worsening after reducing or stopping Cosentyx may manifest as increased skin lesions (red, scaly patches).
Evaluator decision: absent from the label; no label citation/text provided to verify.
For psoriatic arthritis patients, disease worsening after reducing or stopping Cosentyx may manifest as worsening joint pain and stiffness.
Evaluator decision: absent from the label; no label citation/text provided to verify.
Disease worsening after reducing or stopping Cosentyx may lead to reduced quality of life, including decreased mobility, fatigue, and reduced ability to participate in daily activities.
Evaluator decision: absent from the label; no label citation/text provided to verify.
The patent for Cosentyx is set to expire in 2028.
Evaluator decision: absent from the label; patent expiration is not typically part of prescribing information and no label citation/text was provided.
Contradictions
Important Omissions
FDA label citations or exact prescribing information text for any claim (e.g., section references for INDICATIONS, DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, DRUG INTERACTIONS, USE IN SPECIFIC POPULATIONS).
Importance:
High
Any on-label contraindications, boxed warning status, warnings/precautions, interaction information, and required monitoring/stopping rules from the prescribing information (none were provided/assessed).
Importance:
High
Safety Assessment
Potential Patient Risk:
Medium
Safety-related claims are not verifiable against labeling (e.g., 'rebound effect' and symptom descriptions after stopping/reducing). While no explicit contradiction is identified, the absence of label support increases the risk of relying on inaccurate or non-labeled guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
All extracted claims are marked as absent from the label, and no label citations/text were provided to confirm any prescribing-information alignment.
Suggested Improvement
Provide the FDA label section numbers and/or exact label text for each claim (including any boxed warning, warnings/precautions, dosing/administration, and discontinuation guidance) so each statement can be verified against the prescribing information.